复发或难治性弥漫大B细胞淋巴瘤二线治疗中lisocabtagene maraleucel的成本效益
该研究采用分区生存模型,评估lisocabtagene maraleucel(liso-cel)对比铂类化疗后大剂量化疗联合自体造血干细胞移植用于复发或难治性弥漫大B细胞淋巴瘤二线治疗的成本效益。基于TRANSFORM和TRANSCEND试验等数据,在60岁美国成人代表队列中,liso-cel的增量成本效益比(ICER)为每质量调整生命年(QALY)99669美元(医疗保健部门视角)和68212美元(社会视角),在每QALY 10万美元阈值下具有成本效益。
要点
- liso-cel二线治疗复发或难治性弥漫大B细胞淋巴瘤的ICER为每QALY 99669美元(医疗保健部门视角)。
- 社会视角下ICER为每QALY 68212美元,低于每QALY 10万美元的阈值。
- 某些情景下liso-cel的ICER超过每QALY 10万美元,但仍在美国可接受的每QALY 15万美元范围内。
核心结论
- 在每QALY 10万美元的阈值下,liso-cel二线治疗复发或难治性弥漫大B细胞淋巴瘤具有成本效益。
- 某些情景下liso-cel的ICER超过每QALY 10万美元,但仍在美国可接受的每QALY 15万美元范围内。
- 将生产力损失纳入分析对于捕捉新疗法的更广泛社会价值很重要。
- 尽管这些疗法提供显著的临床获益,但其高昂的购置成本和有限的长期数据严重挑战其经济可持续性。
研究设计与样本
- 采用分区生存模型和标准参数函数,评估liso-cel对比铂类化疗后大剂量化疗联合自体造血干细胞移植的成本效益,时间跨度为一生的视野。
- 分析基于TRANSFORM和TRANSCEND试验、已发表文献和公共数据集计算增量成本效益比(ICER)。
- 分析对象为60岁美国成人代表队列。
主要发现
- 医疗保健部门视角下,liso-cel的ICER为每QALY 99669美元。
- 社会视角下,liso-cel的ICER为每QALY 68212美元。
- 在每QALY 10万美元阈值下证实liso-cel具有成本效益;某些情景下ICER超过该阈值但仍在美国可接受的每QALY 15万美元范围内。
关键数值与推荐
- 成本效益阈值:每QALY 10万美元。
- 美国可接受范围上限:每QALY 15万美元。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T-cell therapy, received the US Food and Drug Administration approval in 2022 for second-line treatment of diffuse large B-cell lymphoma (DLBCL) for patients with refractory disease or early relapse after first-line chemoimmunotherapy. This decision was based on the TRANSFORM study demonstrating improvements in event-free survival with liso-cel compared with standard care. Given the high costs of CAR T-cell therapies, particularly as they transition to second-line treatment, a cost-effectiveness analysis is essential to determine their economic viability. The study used a partitioned survival model with standard parametric functions to evaluate the cost-effectiveness of liso-cel aganist platinum-based chemotherapy followed by high-dose chemotherapy and autologous hematopoietic stem cell transplantation over a lifetime horizon The analysis relied on data from the TRANSFORM and TRANSCEND trials, established literature, and public data sets to calculate the incremental cost-effectiveness ratio (ICER). For a representative cohort of US adults aged 60 years, ICER of liso-cel was $99 669 per quality-adjusted life-year (QALY) from a health care sector perspective and $68 212 per QALY from a societal perspective, confirming its cost-effectiveness at the $100 000 per QALY threshold. Nonetheless, under certain scenarios, liso-cel surpasses this benchmark but remains within the US acceptable range of $150 000 per QALY. A key finding underlines the importance of incorporating productivity losses into such analyses to capture the broader societal values of novel therapies. Although these therapies offer substantial clinical benefits, their high acquisition costs and limited long-term data critically challenge their economic sustainability.
引用
- Choe JH, Yu T, Abramson JS, et al. Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma. Blood Adv. 2024. PMID: 38153350. doi:10.1182/bloodadvances.2023011793
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。